Format

Send to

Choose Destination
See comment in PubMed Commons below
J Hematol Oncol. 2010 Feb 10;3:7. doi: 10.1186/1756-8722-3-7.

Ovarian cancer immunotherapy: opportunities, progresses and challenges.

Author information

1
Department of Immunology, University of Connecticut School of Medicine, Farmington, USA. bliu@up.uchc.edu

Abstract

Due to the low survival rates from invasive ovarian cancer, new effective treatment modalities are urgently needed. Compelling evidence indicates that the immune response against ovarian cancer may play an important role in controlling this disease. We herein summarize multiple immune-based strategies that have been proposed and tested for potential therapeutic benefit against advanced stage ovarian cancer. We will examine the evidence for the premise that an effective therapeutic vaccine against ovarian cancer is useful not only for inducing remission of the disease but also for preventing disease relapse. We will also highlight the questions and challenges in the development of ovarian cancer vaccines, and critically discuss the limitations of some of the existing immunotherapeutic strategies. Finally, we will summarize our own experience on the use of patient-specific tumor-derived heat shock protein-peptide complex for the treatment of advanced ovarian cancer.

PMID:
20146807
PMCID:
PMC2831814
DOI:
10.1186/1756-8722-3-7
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center